Market Intelligence for Congenital Myasthenic Syndrome & Neuromuscular Junction Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CHRNE (Cholinergic Receptor Nicotinic Epsilon Subunit) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | CHRNE Promise-ORF / Lentivirus Full-length ORF for stable cell lines. HEK293T packaged, high titer (>10^8 TU/mL). Sequence Verified. |
View CHRNE Products |
| Antigen / Ion Channel | CHRNE Lentivirus Premade Particles Full-length ORF for stable cell line construction (Essential for multi-pass membrane proteins). |
View CHRNE Products |
| Benchmark Ab | Anti-CHRNE Recombinant Antibody High-affinity positive control for expression validation. |
View CHRNE Products |
| Validator | CHRNE siRNA Set For knockdown verification and specificity controls in cell-based assays. |
View CHRNE Products |
| Co-Expression System | CHRNA1 (Alpha Subunit) Recombinant Protein ECD-Fc fusion for ligand binding studies. High Purity (>95%). Endotoxin <1EU/µg. |
View CHRNA1 Products |
| Beta Subunit | CHRNB1 Lentivirus Beta subunit of the adult muscle nAChR pentameric complex. |
View CHRNB1 Products |
| Fetal Isoform | CHRNG (Gamma Subunit) Lentivirus For comparative developmental toxicity screening vs adult epsilon isoform. |
View CHRNG Products |
| NMJ Pathway | MUSK Recombinant Protein Muscle-specific kinase for AChR clustering assays. Theoretical MW verified by mass spec. |
View MUSK Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Protein Conformation | Lentivirus delivery system ensures native cell-surface expression for Patch Clamp and Calcium Flux assays. |
| Pentameric Assembly Validation (Epsilon-containing AChR) | Full-length CHRNE ORF in Lentiviral vector; compatible with multi-cistronic expression systems for co-transduction with CHRNA1, CHRNB1, CHRND. |
| Adult vs Fetal Isoform Selectivity (Epsilon vs Gamma) | Matched Human/Mouse/Cyno ortholog pairs for CHRNE and CHRNG with sequence-verified ECDs for competitive binding assays. |
| Lack of Reliable Controls | High-purity recombinant benchmark antibodies for flow cytometry and Western blot validation; validated siRNA for knockdown specificity confirmation. |
| Gene Therapy Potency Assays | High-titer Lentivirus (>10^8 TU/mL) with fluorescent reporters for transduction efficiency quantification. |
| False Positives in Screening | Validated siRNA included for rigorous specificity and functional baseline checks. |
Live CHRNE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (CMS)
- ➤ Latest Gene Therapy Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CHRNE-related disorders is transitioning from symptomatic management (acetylcholinesterase inhibitors) to precision genetic medicines. As the epsilon subunit of the adult muscle nicotinic acetylcholine receptor (AChR), CHRNE mutations cause specific subtypes of Congenital Myasthenic Syndrome (CMS), including CMS4B. Key mutations with clinical significance include: impaired association with the alpha CHRNA1 subunit (rs372635; UniProt VAR_021213), rs4790235 (UniProt VAR_048170), and strongly reduced agonist affinity and gating efficiency (rs19391; UniProt VAR_071629). The current R&D wave focuses on AAV-mediated gene delivery to restore functional receptor expression at the neuromuscular junction, alongside pharmacological chaperones targeting folding-deficient mutants. With the rarity of CMS driving orphan drug incentives, expect accelerated regulatory pathways for first-in-class gene therapies targeting CHRNE deficiencies within the next 3-5 years.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Novartis, Sarepta, Biogen | CHRNE-CMS | Functional restoration assays using Lentivirus-stable cell lines expressing pentameric AChR |
| Pharmacological Chaperones | Sanofi, Novartis | Folding-deficient CMS | Surface expression assays (Flow Cytometry) with mutant vs WT CHRNE proteins |
| Antisense Oligonucleotides | Biogen, Ionis | Exon-skipping mutations | Rescue assays in patient-derived cell models using high-titer Lentiviral reporters |
| Complement Inhibitors | AstraZeneca (Alexion) | Myasthenia Gravis (AChR+) | Isoform-specific binding (CHRNE-adult vs CHRNG-fetal) to assess developmental safety |
| Small Molecules (Neuromuscular Blockers) | Various CNS/Neuromuscular Pharma | Neuromuscular Blockade / Reversal | Patch Clamp/Calcium Flux (Need native multimeric assembly) |
Key Mutations in CHRNE (CMS4B)
| Mutation | dbSNP | Clinical Significance | Evidence |
|---|---|---|---|
| Impaired association with alpha CHRNA1 subunit | rs372635 | CMS4B | UniProt Q04844 VAR_021213 |
| rs4790235 | rs4790235 | - | UniProt Q04844 VAR_048170 |
| Strongly reduces agonist affinity and gating efficiency | rs19391 | CMS4B | UniProt Q04844 VAR_071629 |